Submission for OMB Review; Comment Request; The Framingham Study, 3732-3733 [E8-478]
Download as PDF
3732
Federal Register / Vol. 73, No. 14 / Tuesday, January 22, 2008 / Notices
biologics facility responded to a
previous RSVP notice announced in the
Federal Register, you should submit a
request to participate in the program to
the Division of Dockets Management
(HFA–305), Food and Drug
Administration, 5630 Fishers Lane, rm.
1061, Rockville, MD 20852. Submit
electronic requests to https://
www.fda.gov/dockets/ecomments or
https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT:
Lonnie Warren Myers, Division of
Manufacturers Assistance and Training,
Center for Biologics Evaluation and
Research (HFM–49), Food and Drug
Administration, 1401 Rockville Pike,
suite 200N, Rockville, MD 20852–1448,
301–827–2000, FAX: 301–827–3079, email: matt@cber.fda.gov
SUPPLEMENTARY INFORMATION:
encouraging new interested parties to
apply.
I. Background
B. Site Selection
All travel expenses associated with
the site visits will be the responsibility
of CBER; therefore, selection of potential
facilities will be based on the
coordination of CBER’s priorities for
staff training as well as the limited
available resources for this program. In
addition to logistical and other resource
factors to consider, a key element of site
selection is a successful compliance
record with CBER or another agency for
which we have a memorandum of
understanding.
CBER regulates certain biological
products including blood and blood
products, vaccines, and cellular, tissue,
and gene therapies. CBER is committed
to advancing the public health through
innovative activities that help ensure
the safety, effectiveness, and timely
delivery of biological products to
patients. To support this primary goal,
CBER has initiated various training and
development programs to promote high
performance of its compliance staff,
regulatory review staff, and other
relevant staff. CBER seeks to
continuously enhance and update
review efficiency and quality, and the
quality of its regulatory efforts and
interactions, by providing CBER staff
with a better understanding of the
biologics industry and its operations.
Further, CBER seeks to improve: (1) Its
understanding of current industry
practices, and regulatory impacts and
needs; and (2) communication between
CBER staff and industry. CBER initiated
its RSVP in 2005, and through these
annual notices, is requesting those firms
that have previously applied and are
still interested in participating, to
reaffirm their interest, as well as
II. RSVP
A. Regulatory Site Visits
In this program, over a period of time
to be agreed upon with the facility,
small groups of CBER staff may observe
operations of biologics establishments,
including for example blood and tissue
establishments. The visits may include
packaging facilities, quality control and
pathology/toxicology laboratories, and
regulatory affairs operations. These
visits, or any part of the program, are
not intended as a mechanism to inspect,
assess, judge, or perform a regulatory
function, but are meant to improve
mutual understanding and to provide an
avenue for open dialogue between the
biologics industry and CBER.
Dated: January 11, 2008.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E8–1006 Filed 1–18–08; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review;
Comment Request; The Framingham
Study
SUMMARY: Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Heart, Lung, and Blood Institute
(NHLBI), the National Institutes of
Health (NIH) has submitted to the Office
of Management and Budget (OMB) a
request for review and approval the
information collection listed below.
This proposed information collection
was previously published in the Federal
Register on November 6, 2007, page
62659, and allowed 60 days for public
comment. Two comments were
received. The purpose of this notice is
to allow an additional 30 days for public
comment. The National Institutes of
Health may not conduct or sponsor, and
the respondent is not required to
respond to, any information collection
that has been extended, revised, or
implemented on or after October 1,
1995, unless it displays a currently valid
OMB control number.
Proposed Collection: Title: The
Framingham Study. Type of Information
Request: Revision (OMB No. 0925–
0216). Need and Use of Information
Collection: The Framingham Study will
conduct examinations and morbidity
and mortality follow-up in original,
offspring, and third generation
participants for the purpose of studying
the determinants of cardiovascular
disease. Frequency of response: Both
individuals and physicians will be
contacted annually. One response per
contact per year is anticipated from
physicians and informants; participants
will average 1.49 responses to various
components within each annual contact.
Affected public: Individuals or
households; businesses or other for
profit; small businesses or
organizations. Types of Respondents:
Adult men and women; doctors and
staff of hospitals and nursing homes.
The annual reporting burden is as
follows: Estimated Number of
Respondents: 5,569 and Estimated Total
Annual Burden Hours Requested: 5,794.
There are no capital, operating, or
maintenance costs to report.
Number of
respondents
Type of respondents
Average time
per response
Annual hour
burden
4719
850
1.107
0.671
5224
570
Totals ....................................................................................................................................
sroberts on PROD1PC70 with NOTICES
Individuals (Participants and Informants) ....................................................................................
Physicians ....................................................................................................................................
5569
........................
5794
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies should
address one or more of the following
points: (1) Evaluate whether the
VerDate Aug<31>2005
20:38 Jan 18, 2008
Jkt 214001
proposed collection of information is
necessary for the proper performance of
the function of the agency, including
whether the information will have
practical utility; (2) Evaluate the
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
accuracy of the agency’s estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(3) Enhance the quality, utility, and
E:\FR\FM\22JAN1.SGM
22JAN1
Federal Register / Vol. 73, No. 14 / Tuesday, January 22, 2008 / Notices
clarity of the information to be
collected; and (4) Minimize the burden
of the collection of information on those
who are to respond, including the use
of appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
Direct Comments to OMB: Written
comments and/or suggestions regarding
the item(s) contained in this notice,
especially regarding the estimated
public burden and associated response
time, should be directed to the: Office
of Management and Budget, Office of
Regulatory Affairs, New Executive
Office Building, Room 10235,
Washington, DC 20503, Attention: Desk
Officer for NIH. To request more
information on the proposed project or
to obtain a copy of the data collection
plans and instruments, contact: Dr. Paul
Sorlie, Epidemiology Branch, Division
of Prevention and Population Sciences,
NHLBI, NIH, II Rockledge Centre, 6701
Rockledge Drive, Suite 10210, MSC #
7936, Bethesda, MD, 20892–7936, or
call 301–435–0456 (non-toll-free
number), or e-mail your request,
including your address to:
SorlieP@NHLBI.NIH.GOV.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 30 days of the date of
this publication.
Dated: January 8, 2008.
Mike Lauer,
Director, Division of Prevention and
Population Sciences, NHLBI, National
Institutes of Health.
Dated: January 8, 2008.
Suzanne Freeman,
OMB Clearance Officer, NHLBI, National
Institutes of Health.
[FR Doc. E8–478 Filed 1–18–08; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
sroberts on PROD1PC70 with NOTICES
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
VerDate Aug<31>2005
20:38 Jan 18, 2008
Jkt 214001
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Clinical
Neuroscience and Disease.
Date: February 4–5, 2008.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Holiday Inn San FranciscoFisherman’s Wharf, 1300 Columbus Avenue,
San Francisco, CA 94133.
Contact Person: Jerry L. Taylor, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5202,
MSC 7846, Bethesda, MD 20892, 301–435–
1175, taylorje@csr.nih.gov.
Name of Committee: Health of the
Population Integrated Review Group,
Behavioral Genetics and Epidemiology Study
Section.
Date: February 7–8, 2008.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Guest Sites Santa
Monica, 1707 Fourth Street, Santa Monica,
CA 90401.
Contact Person: Elisabeth Koss, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockeldge Drive, Room 3152,
MSC 7770, Bethesda, MD 20892, (301) 435–
1721, kosse@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Molecular
Neurogenetics: Quorum.
Date: February 7, 2008.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Grand Hyatt Washington, 1000 H
Street, NW., Washington, DC 20001.
Contact Person: Robert C. Elliott, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3130,
MSC 7850, Bethesda, MD 20892, 301–435–
3009, elliotro@csr.nih.gov.
Name of Committee: Immunology
Integrated Review Group, Cellular and
Molecular Immunology—A Study Section.
Date: February 7–8, 2008.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Marina del Rey Hotel, 13534 Bali
Way, Marina del Rey, CA 90292.
Contact Person: Samuel C. Edwards, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4200,
MSC 7812, Bethesda, MD 20892, (301) 435–
1152, edwardss@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Psychiatric
Genetics.
Date: February 8, 2008.
Time: 8:30 a.m. to 9 a.m.
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
3733
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott, 5151 Pooks Hill
Road, Bethesda, MD 20814.
Contact Person: Cheryl M. Corsaro, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2204,
MSC 7890, Bethesda, MD 20892, (301) 435–
1045, corsaroc@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, SMEP SBIR.
Date: February 10, 2008.
Time: 7:30 p.m. to 10 p.m.
Agenda: To review and evaluate grant
applications.
Place: The William F. Bolger Center, 9600
Newbridge Drive, Potomac, MD 20854.
Contact Person: Richard J. Bartlett, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4110,
MSC 7814, Bethesda, MD 20892, (301) 435–
6809, bartletr@csr.nih.gov.
Name of Committee: Oncological Sciences
Integrated Review Group, Radiation
Therapeutics and Biology Study Section.
Date: February 11–12, 2008.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Bo Hong, PhD, Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 6194, MSC 7804, Bethesda, MD
20892, (301) 435–5879, hongb@csr.nih.gov.
Name of Committee: Oncological Sciences
Integrated Review Group, Cancer Genetics
Study Section.
Date: February 11–12, 2008.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road, NW.,
Washington, DC 20015.
Contact Person: Zhiqiang Zou, PhD, MD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6190,
MSC 7804, Bethesda, MD 20892, (301) 451–
0132, zouzhiq@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Software
Maintenance and Extension.
Date: February 11, 2008.
Time: 8:30 a.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: Fairmont Washington, DC Hotel,
2401 M Street, NW., Washington, DC 20037.
Contact Person: George W. Chacko, PhD.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5170,
MSC 7849, Bethesda, MD 20892, 301–435–
1245, chackoge@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis panel,
Neurotechnology: Quorum.
Date: February 12–13, 2008.
Time: 8 a.m. to 2 p.m.
E:\FR\FM\22JAN1.SGM
22JAN1
Agencies
[Federal Register Volume 73, Number 14 (Tuesday, January 22, 2008)]
[Notices]
[Pages 3732-3733]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-478]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; Comment Request; The Framingham Study
Summary: Under the provisions of Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National Heart, Lung, and Blood Institute
(NHLBI), the National Institutes of Health (NIH) has submitted to the
Office of Management and Budget (OMB) a request for review and approval
the information collection listed below. This proposed information
collection was previously published in the Federal Register on November
6, 2007, page 62659, and allowed 60 days for public comment. Two
comments were received. The purpose of this notice is to allow an
additional 30 days for public comment. The National Institutes of
Health may not conduct or sponsor, and the respondent is not required
to respond to, any information collection that has been extended,
revised, or implemented on or after October 1, 1995, unless it displays
a currently valid OMB control number.
Proposed Collection: Title: The Framingham Study. Type of
Information Request: Revision (OMB No. 0925-0216). Need and Use of
Information Collection: The Framingham Study will conduct examinations
and morbidity and mortality follow-up in original, offspring, and third
generation participants for the purpose of studying the determinants of
cardiovascular disease. Frequency of response: Both individuals and
physicians will be contacted annually. One response per contact per
year is anticipated from physicians and informants; participants will
average 1.49 responses to various components within each annual
contact. Affected public: Individuals or households; businesses or
other for profit; small businesses or organizations. Types of
Respondents: Adult men and women; doctors and staff of hospitals and
nursing homes. The annual reporting burden is as follows: Estimated
Number of Respondents: 5,569 and Estimated Total Annual Burden Hours
Requested: 5,794.
There are no capital, operating, or maintenance costs to report.
----------------------------------------------------------------------------------------------------------------
Number of Average time Annual hour
Type of respondents respondents per response burden
----------------------------------------------------------------------------------------------------------------
Individuals (Participants and Informants)....................... 4719 1.107 5224
Physicians...................................................... 850 0.671 570
-----------------------------------------------
Totals...................................................... 5569 .............. 5794
----------------------------------------------------------------------------------------------------------------
Request for Comments: Written comments and/or suggestions from the
public and affected agencies should address one or more of the
following points: (1) Evaluate whether the proposed collection of
information is necessary for the proper performance of the function of
the agency, including whether the information will have practical
utility; (2) Evaluate the accuracy of the agency's estimate of the
burden of the proposed collection of information, including the
validity of the methodology and assumptions used; (3) Enhance the
quality, utility, and
[[Page 3733]]
clarity of the information to be collected; and (4) Minimize the burden
of the collection of information on those who are to respond, including
the use of appropriate automated, electronic, mechanical, or other
technological collection techniques or other forms of information
technology.
Direct Comments to OMB: Written comments and/or suggestions
regarding the item(s) contained in this notice, especially regarding
the estimated public burden and associated response time, should be
directed to the: Office of Management and Budget, Office of Regulatory
Affairs, New Executive Office Building, Room 10235, Washington, DC
20503, Attention: Desk Officer for NIH. To request more information on
the proposed project or to obtain a copy of the data collection plans
and instruments, contact: Dr. Paul Sorlie, Epidemiology Branch,
Division of Prevention and Population Sciences, NHLBI, NIH, II
Rockledge Centre, 6701 Rockledge Drive, Suite 10210, MSC
7936, Bethesda, MD, 20892-7936, or call 301-435-0456 (non-toll-free
number), or e-mail your request, including your address to:
SorlieP@NHLBI.NIH.GOV.
Comments Due Date: Comments regarding this information collection
are best assured of having their full effect if received within 30 days
of the date of this publication.
Dated: January 8, 2008.
Mike Lauer,
Director, Division of Prevention and Population Sciences, NHLBI,
National Institutes of Health.
Dated: January 8, 2008.
Suzanne Freeman,
OMB Clearance Officer, NHLBI, National Institutes of Health.
[FR Doc. E8-478 Filed 1-18-08; 8:45 am]
BILLING CODE 4140-01-P